Safety and Efficacy of Plant-based Diets in Hemodialysis Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Receiving thrice-weekly outpatient HD treatments for end-stage renal disease
- 3-month mean serum potassium and phosphorus concentrations of >4.5 mEq/L and >4.0 mg/dL, respectively
- No prior episodes of moderate-severe hyperkalemia (potassium ≥6.5 mEq/L) in the past 6 months
- Deemed appropriate for the intervention by the patient's nephrologist, considering the patient's prognosis, cognition and pending treatments (e.g., kidney transplant)
Exclusion Criteria:
- Change in medications that alter potassium homeostasis (e.g., RAAS inhibitors, diuretics, beta-blockers) in the last month
- Diagnosed with bowel diseases or syndromes (e.g., bowel obstruction, major GI surgery, short-bowel syndrome, irritable bowel syndrome, inflammatory bowel disease, chronic diarrhea)
- Anemic, defined as a serum hemoglobin concentration <9.0 g/dL
- Inadequate dialysis efficacy, defined as a Kt/V of <1.2
- Dietary restrictions (e.g., allergies) or otherwise unable/unwilling to adhere to study diets (excludes dietary restrictions on high-potassium foods)
- Pregnant or planning to become pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hemodialysis Patients
Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23.
The participants will be transitioned gradually to a plant-rich diet
|
Adapted from National Kidney Foundation guidelines for HD1
•¼ Animal, ¾ Plant Proteins •½ Refined, ½ Whole Grain
•¼ Animal, ¾ Plant Proteins
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pre-dialysis serum potassium concentrations.
Time Frame: Day 1
|
Pre-dialysis blood samples will be collected by dialysis center staff, and delivered to the Tisch Laboratory by study staff on each dialysis day.
|
Day 1
|
|
Pre-dialysis serum phosphorus concentrations.
Time Frame: Day 7
|
Post-prandial blood tests will be obtained after the participant consumed the standard meal providing 20% of estimated energy requirements corresponding to the research diet
|
Day 7
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: David St Jules, MD, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17-00455
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Disease
-
NCT01875523CompletedEnd-Stage Renal Disease | Renal Failure, Chronic
-
NCT00882557CompletedEnd-stage Renal Disease | Renal Failure Chronic Requiring Hemodialysis
-
NCT01228279CompletedEnd-stage Renal Disease (ESRD) | Kidney Disease
-
NCT04912050CompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on Dialysis
-
NCT01435174CompletedCardiovascular Disease | End-stage Renal Disease
-
NCT00063817CompletedKidney Transplantation | End-stage Renal Disease | Renal Transplantation
-
NCT03227770CompletedEnd-stage Renal Disease
-
NCT00931970Active, not recruitingEnd-Stage Renal Disease
-
NCT04182438UnknownEnd-stage Renal Disease
-
NCT02194946UnknownEnd-Stage Renal Disease
Clinical Trials on Standard Diet
-
NCT00545727CompletedType 1 Diabetes | Type 2 Diabetes | Impaired Glucose Metabolism
-
NCT04845724Completed
-
NCT02939378Unknown
-
NCT02442024Unknown
-
NCT05658263CompletedSarcopenia | Dysbiosis | Colon Cancer
-
NCT04143633UnknownIBS - Irritable Bowel Syndrome | UC - Ulcerative Colitis | IBD - Inflammatory Bowel Disease
-
NCT01716429WithdrawnObesity | Overweight | Infertility | Polycystic Ovarian Syndrome